StockData

Ardelyx vs CorMedix

ARDX and CRMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARDX and CRMD compare

Ardelyx is the larger company, worth 2.2 times as much as CorMedix ($792M against $364M).

CorMedix grew revenue faster over the last twelve months (281% versus 16.8% for Ardelyx).

CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −12.4% at Ardelyx.

CorMedix scores higher on the StockData Score (13 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARDXCRMD
Size and price
Market cap$792M$364M
Share price$3.18$4.67
Change, 1 year−45.7%−58.5%
Change, 5 years256%−7.9%
Beta (5Y)1.090.49
Employees489191
StockData Score
Total score913 (better)
Valuation score2 (better)1
Growth score33
Performance score34 (better)
Health score15 (better)
Dividend score00
Valuation
P/S1.8×0.8× (better)
P/B5.3×0.8× (better)
EV/EBITDA–0.5×
P/FCF–1.5×
FCF yield−2.3%68.8% (better)
Fair value$7.61–
Margin of safety58.2%–
Growth
Revenue growth (TTM)16.8%281% (better)
Revenue growth, 5Y average122%320% (better)
Net income growth (TTM)–266%
Profitability
Gross margin94.4% (better)82.8%
Operating margin−7.9%47.0% (better)
Net margin−12.4%40.5% (better)
FCF margin−4.0%54.2% (better)
Return on equity−38.6%54.9% (better)
Return on invested capital–171%
Financial health
Debt / equity–0.00
Interest coverage−1.6×–
Current ratio3.34 (better)2.56
Altman Z-score−0.102.01 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield–−0.28%
Shareholder yield0.00% (better)−0.28%
Ownership
Held by institutions71.2%56.5%
Held by insiders6.9%3.3%
Insider net buying, 12 months−$1.9M−$1.6M (better)
Short interest, % of float12.6%18.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.